Venus Remedies Limited

NSEI:VENUSREM Stock Report

Market Cap: ₹4.8b

Venus Remedies Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Ashutosh Jain

Chief executive officer

₹7.1m

Total compensation

CEO salary percentage97.0%
CEO tenure17.8yrs
CEO ownershipn/a
Management average tenure4yrs
Board average tenure3.7yrs

Recent management updates

Shareholders May Not Be So Generous With Venus Remedies Limited's (NSE:VENUSREM) CEO Compensation And Here's Why

Sep 17
Shareholders May Not Be So Generous With Venus Remedies Limited's (NSE:VENUSREM) CEO Compensation And Here's Why

Recent updates

Shareholders May Not Be So Generous With Venus Remedies Limited's (NSE:VENUSREM) CEO Compensation And Here's Why

Sep 17
Shareholders May Not Be So Generous With Venus Remedies Limited's (NSE:VENUSREM) CEO Compensation And Here's Why

Venus Remedies Limited (NSE:VENUSREM) Held Back By Insufficient Growth Even After Shares Climb 26%

Jun 14
Venus Remedies Limited (NSE:VENUSREM) Held Back By Insufficient Growth Even After Shares Climb 26%

Venus Remedies (NSE:VENUSREM) Could Easily Take On More Debt

Jun 13
Venus Remedies (NSE:VENUSREM) Could Easily Take On More Debt

Venus Remedies Limited (NSE:VENUSREM) Not Doing Enough For Some Investors As Its Shares Slump 26%

Mar 14
Venus Remedies Limited (NSE:VENUSREM) Not Doing Enough For Some Investors As Its Shares Slump 26%

Calculating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)

Oct 31
Calculating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)

Venus Remedies (NSE:VENUSREM) Seems To Use Debt Rather Sparingly

Jun 03
Venus Remedies (NSE:VENUSREM) Seems To Use Debt Rather Sparingly

Estimating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)

Jul 15
Estimating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)

Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

May 31
Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

I Ran A Stock Scan For Earnings Growth And Venus Remedies (NSE:VENUSREM) Passed With Ease

Mar 30
I Ran A Stock Scan For Earnings Growth And Venus Remedies (NSE:VENUSREM) Passed With Ease

Why Investors Shouldn't Be Surprised By Venus Remedies Limited's (NSE:VENUSREM) 25% Share Price Plunge

Feb 24
Why Investors Shouldn't Be Surprised By Venus Remedies Limited's (NSE:VENUSREM) 25% Share Price Plunge

Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

Feb 01
Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

Here's Why We Think Venus Remedies (NSE:VENUSREM) Is Well Worth Watching

Nov 16
Here's Why We Think Venus Remedies (NSE:VENUSREM) Is Well Worth Watching

Venus Remedies Limited's (NSE:VENUSREM) Stock Is Going Strong: Have Financials A Role To Play?

Mar 11
Venus Remedies Limited's (NSE:VENUSREM) Stock Is Going Strong: Have Financials A Role To Play?

We Think Venus Remedies (NSE:VENUSREM) Is Taking Some Risk With Its Debt

Jan 14
We Think Venus Remedies (NSE:VENUSREM) Is Taking Some Risk With Its Debt

Does Venus Remedies's (NSE:VENUSREM) Statutory Profit Adequately Reflect Its Underlying Profit?

Nov 23
Does Venus Remedies's (NSE:VENUSREM) Statutory Profit Adequately Reflect Its Underlying Profit?

Is Venus Remedies (NSE:VENUSREM) A Risky Investment?

Sep 22
Is Venus Remedies (NSE:VENUSREM) A Risky Investment?

CEO Compensation Analysis

How has Ashutosh Jain's remuneration changed compared to Venus Remedies's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024n/an/a

₹349m

Sep 30 2024n/an/a

₹221m

Jun 30 2024n/an/a

₹285m

Mar 31 2024₹7m₹7m

₹285m

Dec 31 2023n/an/a

₹290m

Sep 30 2023n/an/a

₹255m

Jun 30 2023n/an/a

₹209m

Mar 31 2023₹7m₹7m

₹266m

Dec 31 2022n/an/a

₹157m

Sep 30 2022n/an/a

₹181m

Jun 30 2022n/an/a

₹359m

Mar 31 2022₹7m₹7m

₹407m

Dec 31 2021n/an/a

₹756m

Sep 30 2021n/an/a

₹816m

Jun 30 2021n/an/a

₹715m

Mar 31 2021₹4m₹4m

₹618m

Dec 31 2020n/an/a

₹213m

Sep 30 2020n/an/a

₹87m

Jun 30 2020n/an/a

-₹40m

Mar 31 2020₹3m₹3m

-₹100m

Dec 31 2019n/an/a

-₹161m

Sep 30 2019n/an/a

-₹269m

Jun 30 2019n/an/a

-₹269m

Mar 31 2019₹3m₹3m

-₹286m

Mar 31 2018₹3m₹3m

-₹307m

Compensation vs Market: Ashutosh's total compensation ($USD81.66K) is above average for companies of similar size in the Indian market ($USD41.11K).

Compensation vs Earnings: Ashutosh's compensation has been consistent with company performance over the past year.

CEO

Ashutosh Jain (47 yo)

17.8yrs

Tenure

₹7,145,217

Compensation

Mr. Ashutosh Jain, B.A., LL B serves as Chief Executive Officer at Venus Remedies Limited. He has been an Whole-Time Director of Venus Remedies Limited since May 2007 and serves as its Head of Legal, Regul...

Leadership Team

NamePositionTenureCompensationOwnership
Pawan Chaudhary
Chairman15.3yrs₹12.77m12.82%
₹ 617.1m
Ashutosh Jain
CEO, Head of Legalno data₹7.15mno data
Manu Chaudhary
Joint MDno data₹12.53m11.73%
₹ 564.6m
Akshansh Chaudhary
CTO & Executive Time Director4yrs₹5.19m0.000010%
₹ 481.3
Peeyush Jain
Deputy MDno data₹7.69m0.00037%
₹ 17.8k
Ajeet Kapoor
AVP of Accounts & Head CAAR Divisionno datano datano data
Jitendra Singh
Chief General Manager of Administrationno datano datano data
Neha Kodan
Company Secretary & Compliance Officer13.8yrsno datano data
Manav Soni
Senior Vice President of Plant & Commercial5.1yrsno datano data
Rakesh Pandita
Chief General Manager of Secretarial & Banking4yrsno datano data
Saransh Chaudhary
CEO of VMRC4yrsno datano data
Aditi Chaudhary
President International Business2yrsno datano data

4.0yrs

Average Tenure

53yo

Average Age

Experienced Management: VENUSREM's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Pawan Chaudhary
Chairman15.3yrs₹12.77m12.82%
₹ 617.1m
Ashutosh Jain
CEO, Head of Legal17.8yrs₹7.15mno data
Manu Chaudhary
Joint MD19.3yrs₹12.53m11.73%
₹ 564.6m
Akshansh Chaudhary
CTO & Executive Time Director2.8yrs₹5.19m0.000010%
₹ 481.3
Peeyush Jain
Deputy MDno data₹7.69m0.00037%
₹ 17.8k
Jagdish Sharma
Non-Executive Independent Directorless than a yearno datano data
Navdeep Sud
Independent Non-Executive Director4.7yrs₹80.00kno data
Savita Gupta
Independent Non-Executive Directorno data₹50.00kno data
NPS Monga
Independent Non-Executive Director1.8yrsno datano data
Anil Kumar
Non-Executive Independent Directorless than a yearno datano data

3.7yrs

Average Tenure

54yo

Average Age

Experienced Board: VENUSREM's board of directors are considered experienced (3.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 19:56
End of Day Share Price 2025/02/07 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Venus Remedies Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ashish KushwahaFirstCall Research
Nagaraju AirruvaFirstCall Research